SARS-CoV-2 antibody testing-questions to be asked.

Antibody response COVID-19 diagnostic pathway external quality assurance immunity immunoassay neutralization assay respiratory tract infections serologic tests severe acute respiratory syndrome coronavirus 2

Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 30 04 2020
revised: 18 05 2020
accepted: 25 05 2020
pubmed: 2 6 2020
medline: 17 7 2020
entrez: 2 6 2020
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field.

Identifiants

pubmed: 32479758
pii: S0091-6749(20)30739-9
doi: 10.1016/j.jaci.2020.05.020
pmc: PMC7256507
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-43

Informations de copyright

Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Références

Int J Infect Dis. 2020 May;94:49-52
pubmed: 32251798
Front Med (Lausanne). 2021 Mar 15;8:595773
pubmed: 33791320
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Ageing Res Rev. 2020 Sep;62:101091
pubmed: 32454090
J Clin Virol. 2005 Sep;34(1):22-5
pubmed: 16087120
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
J Infect Dis. 2020 Jun 16;222(1):17-25
pubmed: 32296837
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
Pediatr Allergy Immunol. 2020 Jul;31(5):560-564
pubmed: 32319131
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Ann Lab Med. 2020 Mar 31;40(5):351-360
pubmed: 32237288
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Influenza Other Respir Viruses. 2013 Sep;7(5):872-86
pubmed: 23331969
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Diagnostics (Basel). 2020 Apr 05;10(4):
pubmed: 32260471
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
Emerg Microbes Infect. 2020 Dec;9(1):833-836
pubmed: 32306864
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
J Immunol. 2013 Aug 1;191(3):993-9
pubmed: 23873158
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Nat Rev Immunol. 2020 Jun;20(6):352
pubmed: 32346091
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
J Virol. 2005 May;79(9):5288-95
pubmed: 15827143
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Immunol. 1969 May;102(5):1109-18
pubmed: 4306070
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
BMC Infect Dis. 2013 Sep 16;13:433
pubmed: 24040960
J Infect. 2020 Jul;81(1):e80-e81
pubmed: 32283140

Auteurs

Mustafa K Özçürümez (MK)

Department of Laboratory Medicine of the Medical Clinic at the University Medical Center Knappschaftskrankenhaus Bochum, Ruhr University, Bochum, Germany. Electronic address: mustafa@ozcurumez.de.

Andreas Ambrosch (A)

Institute of Laboratory Medicine, Microbiology and Hygiene, Barmherzige Brüder Hospital, Regensburg, Germany.

Oliver Frey (O)

Institute of Laboratory Medicine, Brandenburg Medical School, Brandenburg an der Havel, Germany; Institute of Medical Diagnostics, Berlin, Germany.

Verena Haselmann (V)

Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.

Stefan Holdenrieder (S)

Institute for Laboratory Medicine, German Heart Centre, Technical University Munich, Munich, Germany.

Michael Kiehntopf (M)

Department of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Jena, Germany.

Michael Neumaier (M)

Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.

Michael Walter (M)

Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical Center, Rostock, Germany; Institute of Laboratory Medicine, Clinical Chemistry, and Pathobiochemistry, Charité University Medical Center, Berlin, Germany.

Folker Wenzel (F)

Faculty of Medical and Life Sciences, Hochschule Furtwangen, Furtwangen, Germany.

Roman Wölfel (R)

Bundeswehr Institute of Microbiology, Munich, Germany; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.

Harald Renz (H)

Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universität Marburg, German Center for Lung Research (DZL), Marburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH